4-Aminopyridine

4 - 氨基吡啶
  • 文章类型: Consensus Development Conference
    Most fire-related deaths are attributable to smoke inhalation rather than burns. The inhalation of fire smoke, which contains not only carbon monoxide but also a complex mixture of gases, seems to be the major cause of morbidity and mortality in fire victims, mainly in enclosed spaces. Cyanide gas exposure is quite common during smoke inhalation, and cyanide is present in the blood of fire victims in most cases and may play an important role in death by smoke inhalation. Cyanide poisoning may, however, be difficult to diagnose and treat. In these children, hydrogen cyanide seems to be a major source of concern, and the rapid administration of the antidote, hydroxocobalamin, may be critical for these children.European experts recently met to formulate an algorithm for prehospital and hospital management of adult patients with acute cyanide poisoning. Subsequently, a group of European pediatric experts met to evaluate and adopt that algorithm for use in the pediatric population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • DOI:
    文章类型: Journal Article
    多发性硬化症(MS)是一种复杂的慢性,疾病进展导致患者生活质量(QOL)下降,管理式护理组织成本高。目前,疾病修饰治疗(DMT)构成了MS患者的平台药物治疗。尽管它们的功效,对于许多服用DMT的患者,几乎没有证据表明它们对生活质量的影响。流动性受损会造成直接和间接成本。患有步态障碍的MS的年度直接医疗费用平均每位患者近21,000美元。流动性下降也与更高的缺勤率有关,从而提高间接成本。Dalfampridine已被证明可以改善MS患者的步行。dalfampridine的作用可以通过改善步行能力来补充DMT的作用,这是整体活动的关键组成部分,也是许多MS患者的主要关注点。改善步行可能有助于控制与MS护理相关的一些直接和间接成本。
    Multiple sclerosis (MS) is a complex chronic, progressing disease that contributes to poor quality of life (QOL) for patients and high costs for managed care organizations. Currently, disease-modifying treatments (DMTs) constitute the platform pharmacotherapy for MS patients. Despite their efficacy, for many patients taking DMTs there is little evidence of their effect on QOL in general or symptom management. Impaired mobility contributes to direct and indirect costs. Annual direct medical costs for MS with gait impairment average nearly $21,000 per patient. Decreased mobility is also associated with higher absenteeism rates, thus raising indirect costs. Dalfampridine has been shown to improve walking in patients with MS. The effects of dalfampridine can complement those of DMTs by improving walking ability as a key component of overall mobility and a primary concern among many MS patients. Improved walking could potentially help contain some of the direct and indirect costs associated with MS care.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号